Loading...
•
Mar 31, 2021
Abeona Therapeutics Q1 2021 Earnings Report
Abeona Therapeutics reported first quarter results, strengthened leadership with new appointments, and advanced clinical programs towards key milestones.
Key Takeaways
Abeona Therapeutics focused on bolstering operational experience, delivering operational excellence, and prioritizing preclinical eye programs. The company appointed a new SVP, Head of Research and Clinical Development, strengthened the Board of Directors, and advanced clinical programs, including EB-101 and ABO-102. Cash, cash equivalents, and short-term investments totaled $86.8 million as of March 31, 2021.
Appointed Dr. Vishwas Seshadri as Senior Vice President and Head of Research and Clinical Development.
Strengthened Board of Directors with the appointment of four new independent members.
EB-101 VITAL trial remains on track for activating a second study site in the Northeast in the second half of 2021.
Preparing for the FDA Type B meeting in June to discuss the ABO-102 Transpher A study data and potential BLA path.
Abeona Therapeutics
Abeona Therapeutics
Forward Guidance
Abeona Therapeutics believes it has sufficient cash resources to build on momentum and fund current development and operating plans through achieving key anticipated milestones including multiple potential regulatory submissions.